🔗 Share this article

While the United States continues making sweeping revisions to its vaccine schedules, one figure has emerged somewhat surprisingly: Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on COVID-19 shots during the pandemic and has concentrated on potential fatalities following COVID-19 vaccination in her recent time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Schedule

Agency leaders had intended to announce major revisions to the pediatric vaccine schedule recently, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of alignment with many the world with no evidence for improved outcomes. The planned update has been delayed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this calendar year.

A New Direction at the Agency

The acting appointment might represent a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the FDA – and it signals a increased emphasis upon rolling back already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing certain pediatric immunization guidelines in the US to become more like the Danish model, a country with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Qualifications

Dr. Høeg has little discernible experience in drug development, regulation or leadership, which has been typical for past directors of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in running a major agency. She lacks background in pharmaceutical oversight.”

Past heads of the center would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who headed the center have had.”

The drug center has an immense portfolio at the agency, the former commissioner emphasized.

“Many people just focuses on the novel medication approvals, but the generic program authorizes thousands of generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and every single one must be supervised,” Dr. Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial administrative aspect to the position, which oversees over 5,000 personnel. “It’s a massive management job, if you perform it correctly,” Woodcock said.

Agency Reaction and Controversial Policies

When asked about questions about Dr. Høeg's fitness for the role and whether this selection indicates greater collaboration among FDA leaders on immunizations, a press secretary responded that the “questions stem from incorrect presumptions”.

“This background aligns with the duties of her role,” the representative said, noting the period Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s recently launched priority voucher program, a controversial expedited medication authorization process that allegedly worried her former heads. “By what process are these drugs being chosen for this voucher program? Who is making the choices?” Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he stated, “the FDA seems to be moving towards less stringent rules of most medications, except for vaccines.”

Public Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, track record, some experts observe. She authored a study using unconfirmed public submissions to assess the incidence of myocarditis following COVID-19 immunization. She advised the state of Florida top health official Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the new administration included changing regulations for recently developed shots and ending “non-essential” immunizations, she stated after the election on a online show. At the FDA, Høeg has according to sources floated the idea of excluding teenage boys from receiving Covid vaccines.

“She’s an complete dogmatist who commences with her conclusions and tailors the evidence to accommodate the data in a very disingenuous, dishonest manner,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|